The act allocates billions of dollars for purchasing vaccines to be used in the event of a bioterrorism attack. A key provision in this act is the allowance of stockpiling medicines and vaccines that have not yet been tested for safety in humans. This is allowed because testing the efficacy of these treatments would also require exposing humans to the chemical, biological, or radioactive threats that they are intended to treat.